Phase 2
Completed N=26
Pupil Dilation for Treatment of IFIS
Intraoperative Floppy Iris Syndrome
Source: ClinicalTrials.gov NCT03760185 ↗
Enrolled (actual)
26
Serious AEs
7.7%
Results posted
Apr 2022
Primary outcomePrimary: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye — 6.76; 7.17 millimeters
Summary
A novel intervention for targeting the treatment of Intraoperative Floppy Iris Syndrome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye |
6.76; 7.17 | — |
| SECONDARY Change in Pupil Diameter of Each Eye After Dilation at the Start of the Study Compared to Pupil Post Dilating Drops at the End of the Study |
0.39; 0.91 | — |
Eligibility Criteria
Inclusion Criteria
- Adults (18 years old or greater) 3. History of having taken, or currently taking any systemic alpha blocker 2. Ability to consent themselves 3. Ability to apply eye drops themselves TID for 7 days
Exclusion Criteria
- Subjects with untreated hypertension or baseline BP >160
- Subjects with Thyrotoxicosis
- Pregnant women or women trying to conceive
- Prisoners
- Inability consent
- Subjects with anatomical narrow angles or who have never had a dilated eye exam
- Subjects currently prescribed brimonidine tartrate for glaucoma
- Subjects who take topical or systemic alpha agonists
- Patients who take monoamine oxidase (MAO) inhibitors
- Patients with known severe cardiovascular disease
Data sourced from ClinicalTrials.gov (NCT03760185). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.